During a live event, Steven I. Robinson, MBBS, discussed guideline-concordant active surveillance and systemic therapies for managing desmoid tumors.
Treating Patients With Progressing Desmoid Tumors
During a live event, Steven I. Robinson, MBBS, discussed desmoid tumor statistics and management for symptomatic progression.
During a live event, Tony Philip, MD, recommended tailored imaging intervals and avoiding surgery and radiation for desmoid tumors.
During a live event, Tony Philip, MD, and participants discussed molecular profiling and active surveillance for desmoid tumor management.
During a live event, Richard F. Riedel, MD, discussed key efficacy and safety outcomes from the phase 3 DeFi trial in patients with progressing desmoid tumors.
During a live event, Richard F. Riedel, MD, discussed Desmoid Tumor Working Group and NCCN guidelines for treating patients with desmoid tumors.
Nam Quoc Bui, MD, discusses survival, symptom control, and ovarian toxicity in the DeFi trial of nirogacestat in patients with desmoid tumors.
During a live event, Nam Quoc Bui, MD discussed desmoid tumors, their presentation, and treatment.
Mark Agulnik, MD, discusses the efficacy and adverse events in the DeFi trial for patients with desmoid tumors given nirogacestat.
Mark Agulnik, MD, discusses the intricacies of desmoid tumors that can be recognized before starting treatment for patients.